Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 9/20 | 0.37 |
| ▸ | AKT2 | P31751 | 8/20 | 0.37 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.35 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17823022 | 0.99 | DRD2 (0.37) | AKT1AKT2AKT3MAPK14SCD5 | |
| SCHEMBL17823089 | 0.98 | AKT1 (0.37) | AKT1AKT2AKT3MAPK14SCD5 | |
| SCHEMBL17822982 | 0.96 | AKT1 (0.38) | AKT1AKT2AKT3MAPK14SCD5 | |
| Hydrochloric Acid SCHEMBL17823114 | 0.96 | AKT1 (0.37) | AKT1AKT2AKT3MAPK14SCD5 | |
| SCHEMBL17823113 | 0.90 | CREBBP (0.39) | AKT1AKT2AKT3MAPK14CTSS | |
| Hydrochloric Acid SCHEMBL19715273 | 0.89 | CREBBP (0.38) | AKT1AKT2AKT3MAPK14CTSS | |
| SCHEMBL17823037 | 0.89 | ALOX5 (0.39) | MAPK14RAF1ERCC1ERCC4 | |
| SCHEMBL17823029 | 0.88 | MAPK14 (0.49) | MAPK14 | |
| Hydrochloric Acid SCHEMBL17823021 | 0.88 | ALOX5 (0.38) | MAPK14RAF1ERCC1ERCC4 | |
| SCHEMBL17823026 | 0.88 | MAPK1 (0.39) | AKT1MAPK14CTSSERCC1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230277-B1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2019-09-18 | — | — | EP | claimed |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-05-21 | — | — | US | claimed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | claimed |
| EP-3230277-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Ltd. (CA) | 2017-10-18 | — | — | EP | claimed |
| WO-2016092375-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-16 | — | — | WO | claimed |
| EP-3230277-B1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2019-09-18 | — | — | EP | disclosed |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-05-21 | — | — | US | disclosed |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-05-21 | — | — | US | disclosed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | AKT1 1351/4885AKT2 2118/4885AKT3 1735/4885 |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | BRD4, BRD3, BRD1 | AKT1 1351/4885AKT2 2118/4885AKT3 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.